Vascarta
Vascarta is a clinical-stage pharmaceutical company dedicated to advancing treatments for pain, inflammation, and chronic diseases through innovative technologies such as transdermal drug delivery and linker chemistry. Their core assets include Vasporta™, a patented transdermal delivery platform, VAS-101 (Vasceptor®), a curcumin-based anti-inflammatory candidate, and an oncology linker platform. The company focuses on conditions like Sickle Cell Disease, Osteoarthritis, Cancer, and Aging, aiming to improve therapeutic efficacy, safety, and patient experience. Vascarta's research and clinical programs are supported by extensive scientific studies, patents, and collaborations with leading institutions, with a mission to revolutionize healthcare with scalable, natural, and effective solutions.
Industries
Nr. of Employees
small (1-50)
Vascarta
Summit, New Jersey, United States, North America
Products
Topical/transdermal curcuminoid clinical candidate (topical gel)
A topical gel formulation delivering curcuminoids systemically via transdermal absorption to target inflammation, pain, and vascular dysfunction; under Phase 1 clinical evaluation for sickle cell disease and osteoarthritis.
Ex vivo blood biopreservation adjunct
A formulation and method for treating stored red blood cells ex vivo to reduce oxidative injury, increase ATP, and mitigate storage lesions prior to transfusion.
VASCEPTOR®
A novel solvent-based formulation of concentrated curcuminoids developed for effective skin penetration and delivery of high amounts of bioactive curcuminoids directly to the circulation, improving vascular health and multiple indices of health span in rodent models of aging and hypertension.
Vasceptor® (VAS-101)
Harnesses the established anti-inflammatory and pain-relieving properties of curcumin through transdermal delivery which overcomes the limited bioavailability and suboptimal effectiveness of oral dosing. Phase 1b clinical trials for Sickle Cell Disease and Osteoarthritis completed.
Vasporta™ technology
A delivery technology that enables transdermal delivery of compounds including botanicals and chemotherapeutics, facilitating more convenient administration compared to injections or infusions.
Vascarta Curcumin Topical Drug
A patented topical drug formulation developed by Vascarta that delivers curcumin through the skin to relieve osteoarthritis joint pain and potentially boost nitric oxide production for systemic benefits.
Topical/transdermal curcuminoid clinical candidate (topical gel)
A topical gel formulation delivering curcuminoids systemically via transdermal absorption to target inflammation, pain, and vascular dysfunction; under Phase 1 clinical evaluation for sickle cell disease and osteoarthritis.
Ex vivo blood biopreservation adjunct
A formulation and method for treating stored red blood cells ex vivo to reduce oxidative injury, increase ATP, and mitigate storage lesions prior to transfusion.
VASCEPTOR®
A novel solvent-based formulation of concentrated curcuminoids developed for effective skin penetration and delivery of high amounts of bioactive curcuminoids directly to the circulation, improving vascular health and multiple indices of health span in rodent models of aging and hypertension.
Vasceptor® (VAS-101)
Harnesses the established anti-inflammatory and pain-relieving properties of curcumin through transdermal delivery which overcomes the limited bioavailability and suboptimal effectiveness of oral dosing. Phase 1b clinical trials for Sickle Cell Disease and Osteoarthritis completed.
Vasporta™ technology
A delivery technology that enables transdermal delivery of compounds including botanicals and chemotherapeutics, facilitating more convenient administration compared to injections or infusions.
Vascarta Curcumin Topical Drug
A patented topical drug formulation developed by Vascarta that delivers curcumin through the skin to relieve osteoarthritis joint pain and potentially boost nitric oxide production for systemic benefits.
Services
Collaborative research agreements and exclusive licensing for linker chemistry and transdermal delivery technology with academic and industry partners.
Sponsorship and execution of early-phase clinical studies including safety/tolerability and biomarker endpoints, and collaboration with clinical research organizations and investigator sites.
Collaborative research agreements and exclusive licensing for linker chemistry and transdermal delivery technology with academic and industry partners.
Sponsorship and execution of early-phase clinical studies including safety/tolerability and biomarker endpoints, and collaboration with clinical research organizations and investigator sites.
Expertise Areas
- Transdermal drug formulation and delivery
- Preclinical disease modeling and in vivo efficacy testing
- Clinical trial design and early-phase execution
- Red blood cell biopreservation and transfusion science
Key Technologies
- Topical/transdermal delivery
- Curcuminoid-based pharmaceutical formulations
- Drug–drug linker chemistry for conjugates
- Ex vivo blood treatment/biopreservation